United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer Inc has sued a longtime employee for allegedly stealing "scores" of confidential documents, including some related to its COVID-19 vaccine, as she prepared to jump to a competitor.

Pfizer sues departing employee it says stole COVID-19 vaccine secrets

Pfizer Inc (NYSE: PFE) has sued its former associate director of clinical statistics in a California court to get a handle on allegedly stolen information. The Company's lawsuit focuses on the COVID-19 vaccine, Comirnaty, and two cancer monoclonal antibodies.

Pfizer Sues Former Employee For Stealing Confidential Info On Its Megablockbuster COVID-19 Vaccine

Pfizer's (PFE) stock is up 38.8% this year so far, riding high on the success of its two-shot vaccine for COVID-19.

Pfizer (PFE) COVID Vaccine & Pill Drive Stock Up This Year

Eli Lilly

The need for life-saving drugs won't subside anytime soon -- and that's what Pfizer and Eli Lilly provide.

Got $5,000? 2 Stocks to Buy and Hold Forever

Pfizer Inc (NYSE: PFE) has provided an update on the Phase 2b study of vupanorsen, investigational antisense therapy for cardiovascular (CV) risk reduction and severe hypertriglyceridemia. In the dose-ranging study in subjects with elevated non-HDL-C and triglycerides (TG), the study met its primary endpoint, achieving a statistically significant reduction in non-HDL-C at all doses tested at 24 weeks, compared to placebo.

Pfizer Posts Vupanorsen Data From Mid-Stage Cardiovascular Disease Trial

Moderna

It may determine the future of vaccine sales.

How This News May Represent a Crucial Test for Moderna and Pfizer

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging updates in the coronavirus vaccine.

Will Pfizer ETFs Soar on Positive COVID-19 Vaccine Updates?

Pfizer, Inc. (NYSE:PFE) found huge success with its COVID-19 franchise that includes Comirnaty, the COVID-19 vaccine it co-developed with BioNTech SE (NASDAQ:BNTX), and its yet-to-be authorized oral COVID-19 pill Paxlovid. The Pfizer Analyst: SVB Leerink analyst Geoffrey Porges reiterated a Market Perform rating on Pfizer shares and increased the price target from $48 to $52.

Pfizer's COVID-19 Franchise Could Push Revenue Past $100B In 2022: Analyst

Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.

Covid-19 Vaccine and Pills Will Push Pfizer's Revenue Above $100B Next Year, Analyst Says

There's more to it than being the first to market with its vaccine.

4 Reasons Pfizer Is Now the Ultimate COVID-19 Growth Stock

Pfizer's vaccine sales have a huge impact in 2021, and that will also be the case next year.

Pandemic Winner Pfizer Is About To Have Its Best Year Ever Due To COVID

These might not be the only boosters that the FDA ultimately endorses.

Why FDA Boosters Authorization Could Be More Important for Pfizer and Moderna Than You Might Think

Alibaba

Merck

Sentiment on Wall Street is not great but it is still proper to seek stocks to buy. Today's bunch are fallen angels that should recover soon.

3 Falling-Star Stocks to Buy Into the Holidays

BioNTech SE

The FDA authorizes booster doses of COVID-19 vaccines of PFE/BNTX and MRNA for use in all adults irrespective of the risk of exposure to coronavirus.

FDA Authorizes PFE & MRNA's COVID-19 Boosters for All Adults

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have announced topline results from a longer-term analysis of the safety and efficacy of their COVID-19 Vaccine in individuals 12 through 15 years of age. The updated findings from the Phase 3 trial show that a two-dose series of the Vaccine (30-µg per dose) was 100% effective against COVID-19, measured seven days through over four months after the second dose.

Pfizer-BioNTech's COVID-19 Vaccine Shows 100% Effectiveness In Long Term Analysis In Adolescents

Pfizer and BioNTech said the long-term data, measured from seven days to four months after the second dose, would form the basis of a submission for full regulatory approval.

Pfizer's Covid-19 Shot Offers 100% Long-Term Protection For Young Teens, Trial Shows

Pfizer Inc. PFE, -1.19% and BioNTech SE BNTX, +5.73% said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19. The follow-up test measured seven days through four-plus months after the second dose.

Pfizer and BioNTech say late-stage trial shows vaccine effective for 12- to 15-year-olds

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and BioNTech SE (Nasdaq:BNTX) today announced topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in individuals 12 through 15 years of age. The updated findings from the companies' pivotal Phase 3 trial show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-µg per dose) was 100% effective against COVID-19, measured seven days through over four months after the second

Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age

AbbVie

British American Tobacco

Altria

Medical Properties Trust

AT&T

W. P. Carey

Investors seeking big payouts should consider these seven high-yield stocks from various sectors. They range from pharmaceuticals to REITs.

7 High-Yield Stock Gems for Income-Obsessed Investors

PFE stock has scored a 38% gain in 2021 with a drug Pfizer didn't develop, thanks to the brilliant leadership of CEO Albert Bourla The post Covid Stand-out Pfizer's Albert Bourla Gets My Vote for CEO of the Year appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.

Covid Stand-out Pfizer's Albert Bourla Gets My Vote for CEO of the Year

Johnson & Johnson

Lockheed Martin

Mastercard

Procter & Gamble

PayPal

Visa

These seven companies either have no exposure to inflation or have strong branding and customer loyalty, enabling them to pass higher costs. The post 7 Stocks to Buy for Their Resistance to the 6.2% Monthly Inflation appeared first on InvestorPlace.

7 Stocks to Buy for Their Resistance to the 6.2% Monthly Inflation

Live Nation

Novavax

Here are three COVID-19 stock ideas: a vaccine biotech, a big pharma stock, and an investment in a reopening.

What Are the Top COVID Plays for 2022?

Over 32 million Americans have already received a Covid-19 vaccine booster shot.

CDC Advisors Recommend Letting All U.S. Adults Take A Covid Booster Shot

The CDC's director will need to accept the committee's recommendation, which she's expected to do soon.

CDC panel recommends COVID boosters for all adults

CDC Director Rochelle Walensky signed off on an independent panel's recommendation for all U.S. adults to be eligible for Pfizer and Moderna booster shots.

News for Pfizer Stock (PFE)